-
公开(公告)号:US20240316168A1
公开(公告)日:2024-09-26
申请号:US18586621
申请日:2024-02-26
申请人: Phaim Pharma Ltd.
发明人: Tihamer ORBAN , Jalahej HEYMAN , Nara DAUBENEY , Piers DAUBENEY
IPC分类号: A61K39/00 , A61K38/28 , A61K45/06 , A61P3/10 , A61P5/50 , A61P37/02 , C07K14/00 , C07K14/47 , C07K14/62 , G01N33/68
CPC分类号: A61K39/0005 , A61K38/28 , A61K39/0008 , A61K45/06 , A61P3/10 , A61P5/50 , A61P37/02 , C07K14/001 , C07K14/4713 , C07K14/62 , G01N33/6893 , A61K2039/55 , A61K2039/55505 , A61K2039/55511 , A61K2039/55566 , A61K2039/55588 , A61K2039/57 , G01N2800/42
摘要: A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least one of the polypeptide fragments is antigenic.
-
2.
公开(公告)号:US20240361217A1
公开(公告)日:2024-10-31
申请号:US18770727
申请日:2024-07-12
申请人: Phaim Pharma Ltd.
发明人: Tihamer ORBAN , Jalahej HEYMAN , Nara DAUBENEY , Piers DAUBENEY
IPC分类号: G01N1/40 , A61K35/17 , A61P17/06 , A61P37/06 , C12N5/0783 , C12Q1/02 , G01N1/06 , G01N1/28 , G01N1/36 , G01N1/42 , G01N33/50
CPC分类号: G01N1/4077 , A61K35/17 , A61P17/06 , A61P37/06 , C12N5/0636 , C12Q1/02 , G01N1/06 , G01N1/2813 , G01N1/286 , G01N1/36 , G01N1/42 , G01N33/505 , G01N33/5091 , G01N2001/2873 , G01N2800/24 , G01N2800/56
摘要: Provided are methods of preparing an immune cell sample from a subject having an autoimmune disorder, the method comprising: obtaining a tissue sample from the subject; and isolating a single immune cell in situ from the tissue sample using laser capture microdissection.
-
公开(公告)号:US20240285732A1
公开(公告)日:2024-08-29
申请号:US18571294
申请日:2022-06-16
申请人: PHAIM PHARMA LTD.
发明人: Tihamer ORBAN , Jalahej HEYMAN , Nara DAUBENEY , Piers DAUBENEY
IPC分类号: A61K38/28 , A61M5/00 , C12Q1/6883 , G01N33/50 , G01N33/68
CPC分类号: A61K38/28 , A61M5/003 , C12Q1/6883 , G01N33/505 , G01N33/6866 , C12Q2600/158 , G01N2333/57 , G01N2800/042 , G01N2800/52
摘要: Compositions of peptide fragments of preproinsulin for the treatment of type 1 diabetes and methods for selecting one or more peptide fragments of preproinsulin suitable for subject-specific immunomodulatory therapy for type 1 diabetes. The one or more peptides may be selected based on an autoimmune phenotype for the subject, which may be characterized by a stimulation assay and/or the based on a genotype for one or more genes related to type 1 diabetes.
-
-